Cancer Vaccines for Hematologic Malignancies

Borrello, Ivan; Sotomayor, Eduardo M.

doi:10.1177/107327480200900206

Cited by 23 publications

(16 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The ease of tumour accessibility, the ability of current treatments to achieve a minimal residual state that could be accurately monitored, and the ability of myeloid cells to differentiate in vitro to functional dendritic cells combine to facilitate any intent to generate successful immonotherapeutic strategies (Borrello & Sotomayor, 2002). Therefore, provided a suitable tumour target/s is/are chosen, immunotherapy for haematological malignancies should provide the lead for further development of tumour vaccines.…”

Section: Future Directionsmentioning

confidence: 99%

Cancer‐testis antigens in haematological malignancies

Meklat

Wang

et al. 2007

Br J Haematol

View full text Add to dashboard Cite

SummaryImmunotherapy is an attractive therapeutic option for patients with haematological malignancies. Until recently, the progress in the development of tumour vaccines for haematological malignancies had been slow due to the lack of suitable targets. Cancer-testis (CT) antigens are potentially suitable molecules for tumour vaccines of haematological malignancies because of their high immunogenicity in vivo and their relatively restricted normal tissue distribution. This review evaluates the properties and potential functions of CT antigens. We discuss the expression of CT antigens in patient with haematological malignancies and provide evidence in support of their immunogenicity in vivo in these patients. We also address the role of 'epigenetic' regulation of CT antigens in haematological malignancies and how hypomethylating agents could induce the expression of some of these antigens in tumour cells to overcome the problem of heterogeneity of expression of the antigen within individual tumour specimens. Data implicating the interaction of the promoter genes of some of these CT antigens with the MeCP2 protein also suggest the potential role of the histone deacetylase inhibitors in inducing antigen expression in tumour cells. Finally, we discuss the direction of future research in advancing the development of tumour vaccines for haematological malignancies.

show abstract

Section: Future Directionsmentioning

confidence: 99%

Cancer‐testis antigens in haematological malignancies

Meklat

Wang

et al. 2007

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…To our knowledge there are no published data on clinical studies using cell-based vaccines in lymphoma, although an ongoing phase I clinical trial study of immunotherapy with autologous tumor cell vaccine and interleukin-2 has been reported [68]. This trial was conducted to assess the safety of immunotherapy with autologous tumor cell vaccine and interleukin-2 in patients with stage III, IV, or recurrent follicular lymphoma; to determine the clinical response of patients treated with this regimen; and to assess the immune response of patients treated with this vaccine.…”

Section: Clinical Studiesmentioning

confidence: 95%

Current advances, problems and prospects for vaccine-based immunotherapy in follicular non-Hodgkin's lymphoma

Dermime

Aljurf

2005

Leukemia & Lymphoma

View full text Add to dashboard Cite

Despite advances in chemotherapy, radiotherapy and combined modality treatment, a significant proportion of non-Hodgkin's lymphomas remain incurable. The disease usually responds well to chemotherapy or radiation, but relapses are observed within months to a few years, with frequent failure of subsequent therapies. High-dose chemotherapy with or without radiation and autologous or allogeneic hematopoietic stem cell transplantation provide higher cure rates and longer remissions in certain patients with aggressive lymphomas. However, the higher treatment-related morbidity and mortality of high-dose chemotherapy has driven a search for new and more tumor-specific treatment modalities, such as immunotherapy. Tumor antigens expressed by B-cell lymphomas, such as the "idiotype antigen", are seen as unique and specific target molecules for direct lymphoma immunotherapy. This review will delineate advances, problems and prospects for approaches to anti-B cell lymphoma immunotherapy where pre-clinical studies and proof of principle have been directly translated to patient care.

show abstract

“…Unique tumor-associated antigens may include bcr/abl peptides in CML, AML/ETO or PMLRARa in acute myeloid leukemia (AML). 4,5 Furthermore, idiotypic specific immunoglobulins may act as tumor specific antigens in B-cell lymphoma. 6,7 Mutated oncogenes like P53 and RAS may be expressed in many tumors.…”

Section: Tolerance To Hematological Malignanciesmentioning

confidence: 99%

Immunotherapy of hematological malignancies with dendritic cells

Falkenburg

2004

Hematol J

View full text Add to dashboard Cite

Cancer Vaccines for Hematologic Malignancies

Cited by 23 publications

References 95 publications

Cancer‐testis antigens in haematological malignancies

Cancer‐testis antigens in haematological malignancies

Current advances, problems and prospects for vaccine-based immunotherapy in follicular non-Hodgkin's lymphoma

Immunotherapy of hematological malignancies with dendritic cells

Contact Info

Product

Resources

About